PAVmed Inc. (PAVM)

Overview

PAVmed Inc. is a distinguished medical device company based in the United States, specializing in the innovation of minimally invasive surgical and diagnostic devices aimed at improving patient outcomes. Originally known as PAXmed Inc., the company underwent a name change to PAVmed Inc. in April 2015, signifying a step forward in its mission to lead in the medical device sector. Established in 2014 and headquartered in New York, New York, PAVmed Inc. has swiftly positioned itself as a prominent player in the medical device industry through its development of leading-edge products designed to address critical needs in the medical community.

Products and Services

• CarpX: A patented, single-use, disposable, and minimally invasive surgical device specifically designed for the treatment of carpal tunnel syndrome, a prevalent condition that affects millions globally. CarpX represents a significant advancement in the surgical treatment of this syndrome, offering a less invasive alternative to traditional surgical procedures.
• EsoCheck: An innovative esophageal cell collection device that plays a crucial role in the early detection of esophageal conditions such as adenocarcinoma of the esophagus and Barrett's Esophagus (BE). EsoCheck aims to simplify and enhance the accuracy of diagnostic processes for these potentially life-threatening conditions.
• EsoGuard: A bisulfite-converted next-generation sequencing DNA assay that compliments EsoCheck by providing a sophisticated and accurate method for detecting esophageal dysplasia or early-stage cancer. Together, EsoCheck and EsoGuard offer a comprehensive solution for early detection and monitoring of esophageal health.
• EsoCure: This device is designed to treat dysplastic Barrett's Esophagus (BE) through esophageal ablation, showcasing PAVmed's commitment to not only diagnosing but also treating esophageal conditions. EsoCure represents an innovative approach to managing pre-cancerous conditions effectively.
• PortIO: An implantable intraosseous vascular access device that illustrates PAVmed's dedication to improving long-term vascular access. PortIO is intended to offer a reliable, long-lasting solution for patients requiring chronic intravenous treatments, reducing the need for repeated venous access procedures.
• NextFlo: This product remains under development and aims to revolutionize the field of intravenous fluid and medication administration. NextFlo seeks to provide precise control and administration without the need for complex electronic infusion devices, potentially offering a simpler, more effective option for healthcare providers.
• Veris cancer care platform: PAVmed's foray into the cancer care sector, the Veris platform, is designed to enhance the quality and effectiveness of cancer treatment through advanced diagnostics and patient monitoring. This platform underscores the company's broader commitment to transforming cancer care delivery.